Review
Structural MRI in Huntington's disease and recommendations for its potential use in clinical trials

https://doi.org/10.1016/j.neubiorev.2013.01.022Get rights and content

Abstract

Huntington's disease (HD) results in progressive impairment of motor and cognitive function and neuropsychiatric disturbance. There are no disease-modifying treatments available, but HD research is entering a critical phase where promising disease-specific therapies are on the horizon. Thus, a pressing need exists for biomarkers capable of monitoring progression and ultimately determining drug efficacy. Neuroimaging provides a powerful tool for assessing disease progression. However, in order to be accepted as biomarkers for clinical trials, imaging measures must be reproducible, robust to scanner differences, sensitive to disease-related change and demonstrate a relationship to clinically meaningful measures. We provide a review of the current structural imaging literature in HD and highlight inconsistencies between studies. We make recommendations for the standardisation of reporting for future studies, such as appropriate cohort characterisation and documentation of methodologies to facilitate comparisons and inform trial design. We also argue for an intensified effort to consider issues highlighted here so that we have the best chance of assessing the efficacy of the therapeutic benefit in forestalling this devastating disease.

Highlights

► Structural MRI has the potential to assess progression in clinical trials. ► The most promising biomarkers in HD are striatal and white matter atrophy. ► Consideration of image acquisition, processing and statistical design is essential. ► Appropriate reporting of study design is vital to allow evaluation of the literature.

Introduction

Huntington's disease (HD) is an autosomal-dominantly inherited neurological condition resulting in progressive deterioration of motor, cognitive and neuropsychiatric function. HD typically affects individuals in mid-life, having a 15–20 year disease course. Individuals at risk of developing HD are able to undergo predictive genetic testing and these ‘premanifest’ individuals have provided valuable insights into the natural history of this disease. HD has a devastating effect on patients and their families and there are currently no disease-modifying therapies licensed for treatment. However, HD research is entering a critical phase where promising novel disease-specific therapies are on the horizon (Ross and Tabrizi, 2011). There is, therefore, a pressing need for biomarkers capable of monitoring disease progression and ultimately determining drug efficacy in clinical trials. To date, the most widely used clinical assessment in HD is the Unified Huntington's Disease Rating Scale (UHDRS) (Huntington Study Group, 1996). However, this scale tends to have high inter-rater variability, is subject to floor and ceiling effects and is relatively insensitive in the premanifest stages of the disease. Recently there has been great interest in developing more objective, quantitative measures that might track progression across the disease spectrum including motor, cognitive, neuropsychiatric and imaging assessments (Weir et al., 2011). PREDICT-HD (Paulsen et al., 2008) and TRACK-HD (Tabrizi et al., 2009) are two large multi-site studies that have sought to validate such tools in preparation for clinical trials, and both studies report strong effect sizes for imaging measures even in the very earliest premanifest cohorts (Aylward et al., 2011, Tabrizi et al., 2012).

In order for imaging measures to be accepted as biomarkers, it is important to establish robust methodologies that track disease progression in a clinically meaningful way and are reproducible across multiple sites with different scanner manufacturers and field strengths. There is a wide range of imaging modalities available providing information on macrostructural changes such as atrophy (e.g., structural MRI), microstructural processes such as demyelination (e.g., diffusion weighted imaging), metabolic deficits (magnetic resonance spectroscopy) and functional changes (PET and task- and resting-state functional MRI). Studies are ongoing to establish the relative merits of these approaches (for review see Georgiou-Karistianis, 2009). However, at present, structural brain imaging remains the most widely applied technique and has the greatest documentation of robust multi-site disease-related longitudinal changes from up to 15 years prior to symptom onset through to established disease (Aylward et al., 2011, Georgiou-Karistianis et al., 2013, Tabrizi et al., 2011). Although there are a number of published diffusion and functional imaging studies showing early disease-related dysfunction, we are yet to investigate the sensitivity of such measures in large scale longitudinal studies, so we limit this review to the existing structural imaging literature.

Section snippets

Challenges in current published neuroimaging studies

There have been great advances in neuroimaging techniques over the last decade, and although reproducible group differences across multiple sites and studies (e.g., TRACK-HD and PREDICT-HD) have been demonstrated robustly, there remain a number of significant challenges when comparing cross-sectional and longitudinal findings across the published literature. Two main areas relate to the reporting of sample and neuroimaging characteristics (both acquisition and image processing). The reported

Neuroimaging of the basal ganglia

The most consistently investigated and reported neuropathological characteristic of HD is a significantly progressive volumetric reduction of the striatum, the main input nucleus of the basal ganglia (see Hersh et al., 2004, Vonsattel et al., 1985). These findings have been confirmed and expanded in MRI studies, especially from PREDICT-HD (Paulsen et al., 2008, Paulsen et al., 2010), TRACK-HD (Tabrizi et al., 2009, Tabrizi et al., 2012), and IMAGE-HD (Georgiou-Karistianis et al., 2013). Volume

Neuroimaging of whole brain, CSF and cortex

Whilst early involvement of the striatum is well-documented (Aylward et al., 2004, Ciarmiello et al., 2006, Harris et al., 1999), recently evidence has emerged suggesting there is also widespread cortical involvement in the HD degenerative process. Both cross-sectional and longitudinal global measures such as whole-brain atrophy (Aylward et al., 1998, Aylward et al., 2011, Henley et al., 2009, Paulsen et al., 2010, Rosas et al., 2003, Tabrizi et al., 2012, Wild et al., 2010), grey matter loss (

Neuroimaging of white matter

Recently, there has been accumulating evidence to suggest that WM degeneration may be an important feature in the HD neurodegenerative process. Whilst some studies have failed to detect WM atrophy in early HD (Bohanna et al., 2011, Sritharan et al., 2010) or pre-HD individuals (Rosas et al., 2006), there is now considerable evidence that WM atrophy is evident in both early HD (Aylward et al., 1998, Beglinger et al., 2005, Halliday et al., 1998, Rosas et al., 2003, Tabrizi et al., 2009) and

Cingulate

Pathological studies report cell loss in the cingulate (Thu et al., 2010), yet structural studies have produced conflicting results. Cross-sectional Freesurfer analysis has suggested increased thickness in the anterior cingulate in early HD (Nopoulos et al., 2010, Rosas et al., 2008), but both cross-sectional (Henley et al., 2009, Hobbs et al., 2011, Politis et al., 2011) and longitudinal (Ruocco et al., 2008) studies have demonstrated volume reduction in similar cohorts. Cingulate atrophy

Recommendations for neuroimaging studies

From our review of neuroimaging studies in HD, we conclude that there are sufficient data to justify consideration of structural MRI metrics as potential outcome measures in future clinical trials in both pre-HD and symp-HD. Reproducible group differences (cases vs. controls) have been found in many structural MRI measures, even in individuals who are far from onset. Structural MRI measures that show the most robust longitudinal change (in comparison with age-matched controls) from our review

Future studies

Although several large-scale MRI studies have been conducted in pre-HD and symp-HD, there are still several questions that remain to be answered. Some of these questions may be best addressed though analyses that combine data from multiple studies, which will be facilitated by the availability of MRI data from, for example, in the USA federally mandated repositories of data acquired through NIH-funded studies. Specific questions that need to be addressed include:

  • What method of image analysis is

Conclusions

Here we provide a detailed review of the structural imaging literature to date in HD, highlight discrepancies between studies, and identify possible explanations for these inconsistencies. We recommend that future neuroimaging publications provide detailed characterisation of cohorts, together with clear documentation of methodologies to facilitate comparisons and inform clinical trial design. We argue for an intensified effort to overcome various issues still outstanding as we move closer

References (83)

  • J.S. Paulsen et al.

    Striatal and white matter predictors of estimated diagnosis for Huntington disease

    Brain Research Bulletin

    (2010)
  • A. Peinemann et al.

    Executive dysfunction in early stages of Huntington's disease is associated with striatal and insular atrophy: a neuropsychological and voxel-based morphometric study

    Journal of the Neurological Sciences

    (2005)
  • A. Rizk-Jackson et al.

    Evaluating imaging biomarkers for neurodegeneration in pre-symptomatic Huntington's disease using machine learning techniques

    NeuroImage

    (2011)
  • H.D. Rosas et al.

    Altered white matter microstructure in the corpus callosum in Huntington's disease: implications for cortical “disconnection”

    NeuroImage

    (2010)
  • C.A. Ross et al.

    Huntington's disease: from molecular pathogenesis to clinical treatment

    Lancet Neurology

    (2011)
  • S.J. Tabrizi et al.

    Biological and clinical manifestations of huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data

    Lancet Neurology

    (2009)
  • S.J. Tabrizi et al.

    Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data

    Lancet Neurology

    (2012)
  • S.J. Tabrizi et al.

    Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis

    Lancet Neurology

    (2011)
  • D.W. Weir et al.

    Development of biomarkers for Huntington's disease

    Lancet Neurology

    (2011)
  • E.H. Aylward et al.

    Frontal lobe volume in patients with Huntington's disease

    Neurology

    (1998)
  • E.H. Aylward et al.

    Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons

    Neurology

    (1994)
  • E.H. Aylward et al.

    Basal ganglia volume and proximity to onset in preclinical Huntington's disease

    Archives of Neurology

    (1996)
  • E.H. Aylward et al.

    Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease

    Movement Disorders

    (2000)
  • E.H. Aylward et al.

    Longitudinal change in basal ganglia volume in patients with Huntington's disease

    Neurology

    (1997)
  • E.H. Aylward et al.

    Longitudinal change in regional brain volumes in prodromal Huntington disease

    Journal of Neurology, Neurosurgery and Psychiatry

    (2011)
  • E.H. Aylward et al.

    Onset and rate of striatal atrophy in preclinical Huntington disease

    Neurology

    (2004)
  • Aylward, E. Structural imaging in preclinical HD. Abstracts of the 39th Annual INS Meeting, Journal of the...
  • N. Bechtel et al.

    Tapping linked to function and structure in premanifest and symptomatic Huntington disease

    Neurology

    (2010)
  • L.J. Beglinger et al.

    White matter volume and cognitive dysfunction in early Huntington's disease

    Cognitive and Behavioral Neurology

    (2005)
  • I. Bohanna et al.

    Diffusion tensor imaging in Huntington's disease reveals distinct patterns of white matter degeneration associated with motor and cognitive deficits

    Brain Imaging and Behavior

    (2011)
  • G.N. Brandt et al.

    Structural neuroimaging of the basal ganglia in schizophrenic patients: a review

    Wiener Medizinische Wochenschrift

    (2008)
  • J. Brandt et al.

    Impaired source memory in Huntington's disease and its relation to basal ganglia atrophy

    Journal of Clinical and Experimental Neuropsychology

    (1995)
  • J.R. Campodonico et al.

    When does Huntington's disease begin?

    Journal of the International Neuropsychological Society

    (1998)
  • A. Ciarmiello et al.

    Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease

    Journal of Nuclear Medicine

    (2006)
  • R. Della Nave et al.

    Regional distribution and clinical correlates of white matter structural damage in Huntington disease: a tract-based spatial statistics study

    American Journal of Neuroradiology

    (2010)
  • C. Frost et al.

    Optimizing the design of clinical trials where the outcome is a rate. Can estimating a baseline rate in a run-in period increase efficiency?

    Statistics in Medicine

    (2008)
  • C. Gavazzi et al.

    Combining functional and structural brain magnetic resonance imaging in Huntington disease

    Journal of Computer Assisted Tomography

    (2007)
  • A. Ginestroni et al.

    Magnetization transfer MR imaging demonstrates degeneration of the subcortical and cortical gray matter in Huntington disease

    American Journal of Neuroradiology

    (2010)
  • G.J. Harris et al.

    Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease

    Brain

    (1999)
  • G.J. Harris et al.

    Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington's disease

    Annals of Neurology

    (1992)
  • S.M.D. Henley et al.

    Pitfalls in the use of voxel-based morphometry as a biomarker: examples from Huntington disease

    American Journal of Neuroradiology

    (2010)
  • Cited by (0)

    1

    Equal first authors.

    View full text